B2B Software Technologies Limited Overview
B2B Software Technologies is a Hyderabad-based micro-cap IT services company with roughly 30 years of history. Its core business is implementing, customising and supporting Microsoft Dynamics enterprise resource planning (ERP) and customer relationship management (CRM) systems for small and mid-sized organisations. Its legacy Dynamics competencies were NAV and AX; it now works on Dynamics 365 Business Central. On top of that services core it sells proprietary Microsoft-certified add-on modules: HR & Payroll, Quality Control, Plant Maintenance, and B2B LIFT for life sciences. It also operates GeniusDoc, a medical-practice management system serving the US market through its wholly owned subsidiary, B2B Softech Inc. In August 2025 it launched an "Emerging Technologies" division covering AI, machine learning, large language models (LLMs), agentic chatbots, robotic process automation (RPA), blockchain, cloud migration and cybersecurity. That launch was anchored by a USD 1 million, five-year AI contract with a US oncology practice, which is a related party. FY2026 consolidated revenue was INR 30.46 Cr (+26.2%). The company has no debt, is profitable, paid its first dividend in FY2026, and is promoter-controlled (56.5%).
What the company does. The company has three revenue engines. First, Microsoft Dynamics ERP/CRM implementation and support: business-process analysis, system design, implementation, data migration, training, user acceptance testing (UAT), go-live, hypercare and annual maintenance. Second, proprietary add-on software built on the Dynamics platforms and sold to Dynamics customers, including through other resellers. Screener's AI extraction of the annual report tracks an "add-on sales through resellers" KPI. Third, healthcare IT in the US through the GeniusDoc practice-management/EMR product and, since FY2026, AI and data services for an oncology practice. The company describes itself as a business-solution implementation company in the Microsoft Dynamics space. It offers offshore and onsite solution development for mid-to-large enterprises (Screener summary of the FY2025 annual report).
The company's own description. The company's long-standing self-description is that it is a Microsoft Gold ERP partner and a leading business-solution implementation company in the Microsoft Dynamics space. It specialises in business process analysis, system design, technical expertise, implementation, training and support. Its FY2025 Directors' Report adds the launch of the Emerging Technologies division and describes Microsoft Dynamics CRM and ERP as software that connects people, processes and systems.
Independent characterisation. This is best viewed as a sub-scale, people-intensive Microsoft channel services firm. Employee cost absorbed 62.8% of FY2026 revenue. It has a thin intellectual-property overlay (the add-ons and GeniusDoc) and a small US healthcare foothold that is now driving most incremental growth. The "Gold Certified" label refers to Microsoft's legacy competency framework. Microsoft replaced Gold/Silver competencies with "Solutions Partner" designations under the Microsoft Cloud Partner Program in 2022. The company's current designation is not publicly disclosed in sources reviewed.
Revenue model mix. The company does not disclose a split of product, service, subscription and licence revenue. Disclosed contracts indicate the following mix:
Value-chain position. The company is a downstream system integrator and independent software vendor (ISV) within the Microsoft ecosystem. It depends on Microsoft's product roadmap, licensing and partner-program economics. It does not own a platform.
Customer types and end-markets. The company targets small and mid-sized manufacturers and life-sciences firms: pharmaceutical, biotech, food processing and chemicals, per its LIFT product positioning. Other targets are agribusiness (Kongoni River Farm in Kenya and Ethiopia), US physician practices and oncology centres, and telecoms (named in a PitchBook description). Geographically it serves India, the USA and, more recently, East Africa. It does not disclose a customer count.
Strategy
Stated strategy themes. These are paraphrased from the FY2025 Directors' Report and Regulation 30 disclosures. The company does not hold investor days.
-
Move up the value chain from ERP implementation into emerging technologies. The company has positioned the Emerging Technologies division as its response to rapidly growing demand for innovative and transformative solutions.
-
Leverage the Microsoft Dynamics core. It continues to sell implementation, add-ons and AMC on Business Central and D365, with AI layered on top (the website markets "Microsoft Dynamics 365 AI" and AI agents).
-
Vertical healthcare focus in the US. It pairs GeniusDoc with AI and ML for oncology workflows.
-
Employee alignment. It uses ESOP and RSU schemes to retain talent.
-
Shareholder-return and liquidity initiatives. These include the first dividend, a bonus issue and a proposed stock split.
Strategic initiatives register (last 24 months):
Sustainability / ESG commitments: none disclosed. Cost programmes: none disclosed.
Medium-term financial targets / guidance: none publicly issued. The company does not provide guidance.
Products & Services
A. Microsoft Dynamics services (core)
B. Proprietary add-on IP (Microsoft-certified, built on Dynamics)
C. Healthcare IT (primarily US, via B2B Softech Inc.)
D. Emerging Technologies Division (launched August–September 2025)
Pricing, flagship SKUs and launch versions for the Emerging Technologies offerings are not publicly disclosed. Initial investment was INR 1.00 Cr of capex from internal accruals.
Product Portfolio
| Offering | Description / capabilities | Target customer | Version / year | Pricing model |
|---|---|---|---|---|
Microsoft Dynamics NAV implementation | ERP for small and mid-size organisations covering finance, supply chain and operations | Small and mid-sized manufacturers and distributors | Legacy platform; NAV has been superseded by Business Central | Project fees plus annual maintenance contract (AMC); not disclosed |
Microsoft Dynamics AX / D365 Finance & Operations | Larger-enterprise ERP implementation, upgrade and maintenance | Mid-to-large enterprises | AX legacy; D365 F&O current (company website references NAV, AX and AI) | — |
Dynamics 365 Business Central | Cloud ERP implementation, data migration, training, UAT, go-live, hypercare, AMC | Small and mid-sized businesses incl. agribusiness (Kenya and Ethiopia) | Current; June 2026 order | Milestone-based project fee plus 500 support hours a year (Learnovate order) |
Microsoft Dynamics CRM | CRM implementation | Mid-market | Listed since at least 2009 | — |
Consulting, customisation, cloud migration, support | Business-process analysis, system design, custom development, cloud migration | Existing Dynamics users | Ongoing | Time-and-materials (inferred) |
“—” = not publicly disclosed.
| Product | Description | Target customer | Platform | Pricing |
|---|---|---|---|---|
B2B HR & Payroll | Salary computation, leave and attendance management. Positioned as covering the employee lifecycle from recruitment to exit | Indian and international mid-market employers | NAV / Business Central (implied) | Licence; not disclosed |
B2B Quality Control (NAV & AX) | Integrates quality checks into supply-chain, manufacturing and inventory processes | Manufacturers, regulated industries | NAV and AX | Licence; not disclosed |
B2B Plant Maintenance (NAV) | Plant/equipment maintenance management within ERP | Process and discrete manufacturers | NAV | Licence; not disclosed |
B2B LIFT | Life-sciences ERP vertical (pharma, biotech, food processing, chemicals) | Life-sciences companies | NAV | Licence; not disclosed |
PO Automation add-on | Purchase-order automation | Business Central users | Business Central | Licences sold per country (Kenya and Ethiopia) under the June 2026 order |
| Product / service | Description | Target customer | Notes |
|---|---|---|---|
GeniusDoc | Medical-practitioner / physician practice management system (EMR heritage dating to 2009 listings) | US physician practices | The AGM resolution approved related-party transactions with Antelope Valley Cancer Center "in collaboration with Genius doc" |
Oncology AI program (Antelope Valley Cancer Center) | AI, ML, deep learning, agentic chatbots, data mining, digital workflow transformation and enhanced cybersecurity to improve efficiency, quality of care and operations | US oncology practice (related party) | USD 1,000,000 over 60 months (disclosed 13 August 2025) |
| Practice area | Stated scope |
|---|---|
AI / ML / LLM | Model development, LLM integration |
Agentic chatbots | Conversational and agentic automation; company website now markets "B2B AI Solutions" including AI agents and Dynamics 365 AI |
Blockchain | Blockchain technologies (no named offering) |
RPA and digital workflow transformation | Process automation |
Data mining, warehousing, advanced analytics | Data platforms |
Low-code / no-code tools | Application development |
Cloud migration | Infrastructure modernisation |
Cybersecurity | Security services |
Financial Narrative
Source: Screener.in consolidated data (C-MOTS feed from BSE filings) for FY2022–FY2026; employee cost from Research360; margins and ratios computed by the analyst unless noted. All figures are INR Cr unless stated.
Income statement
Notes on the income statement:
Gross profit: is not reported. Indian IT services filers present costs by nature, not cost of sales. Simply Wall St's own construction shows trailing-twelve-month gross profit of INR 8.65 Cr on INR 29.91 Cr revenue (to December 2025), a gross margin of about 28.9%. That is a third-party definition, not a company disclosure.
Diluted EPS: is not separately disclosed in accessible sources. The ESOP options outstanding (250,325 plus 24,811) are small against 17.38 million shares.
Revenue CAGR: FY2021–FY2026 (5-year) is 15.4%; FY2022–FY2026 (4-year) is 11.2%. Net income CAGR: FY2021–FY2026 is 8.6%; FY2022–FY2026 is 1.5%.
Margin profile
Commentary. The five-year record has three phases.
-
FY2022 peak. Revenue jumped 33.6% and operating margin reached 15.5%. That was the post-pandemic demand surge for cloud ERP in the mid-market.
-
FY2023–FY2024 compression. Revenue was flat at about INR 20 Cr while employee cost rose about 14% over the two years. Operating margin collapsed to 6.0%. In FY2024, other income (treasury yield on about INR 14 Cr of investments) contributed 56% of pre-tax profit. In that year the business was effectively an investment portfolio with a small services operation attached.
-
FY2025–FY2026 re-acceleration. Revenue grew 18.8% and then 26.2%, driven predominantly by the US subsidiary. Operating margin recovered only partially, to about 8%, because headcount cost grew in step: employee cost rose 26.5% in FY2025 and 22.4% in FY2026.
The structural conclusion is that growth has not yet produced operating leverage. Other income still contributes more than a third of pre-tax profit. Quarterly operating margin has swung between 3.5% and 15.0% over the last five quarters, which shows high sensitivity to project timing.
Quarterly trajectory (consolidated, INR Cr)
Q1 FY27 (latest quarter). Revenue was INR 7.39 Cr (+14.2% year-on-year, –8.1% quarter-on-quarter). Operating margin was 7.04% versus 4.33% a year earlier. Net income was INR 0.92 Cr (+41.5%). However, other income of INR 0.73 Cr equalled 60% of pre-tax income. The year-on-year profit improvement is therefore of mixed quality. Standalone Q1 FY27 revenue was INR 3.65 Cr (+14.4%) with net income of INR 0.63 Cr (+6.8%).
Balance sheet
Notes on the balance sheet:
Equity capital: rose to about INR 17.38 Cr after the April 2026 bonus, with an offsetting reduction in reserves of INR 5.79 Cr.
- Cash and equivalents, goodwill/intangibles and working capital are not separately disclosed in accessible sources. Goodwill is presumed nil or immaterial because there have been no acquisitions.
Net debt: is negative (net cash). The company has zero borrowings and INR 18.01 Cr of investments. The liquidity of the investment book (fixed deposits, mutual funds or other) is not disclosed.
Commentary. The balance sheet is pristine but capital-inefficient. About 64% of assets sit in investments against an operating business that needs well under INR 1 Cr of fixed assets. Equity has compounded at about 12% a year purely through retained earnings, and FY2026 was the first year any capital was returned. The INR 18 Cr investment book equals about 48% of the current market capitalisation.
Cash flow
Two points on these figures. Dividends paid are inferred from the financing outflow, which matches INR 1 per share on about 11.59 million pre-bonus shares. FY2026 operating cash flow more than doubled, helped by a fall in debtor days to 13.
Return, leverage and efficiency ratios
How the derived ratios were built and what could not be computed:
Operating ROIC: equals EBIT × (1 – tax rate) divided by year-end (equity – investments). It is analyst-derived.
Current ratio: is not disclosed; the liquidity proxy above stands in for it.
Interest coverage: and net debt/EBITDA are not meaningful because finance cost and debt are zero.
Commentary. Headline ROE of about 12% understates the economics of the operating business. Stripping out the low-yield investment book, operating capital earns about 25% after tax. The value question is therefore capital allocation, not business quality per se.
The rising "inventory days" (8.9 to 32.6) is unusual for a services company. It likely reflects licence stock or unbilled work-in-progress, but the company has not explained it. Rising inventory days combined with collapsing payable days have lengthened the cash conversion cycle from 13 to 42 days, even as debtor days improved.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Ownership | Function | Status |
|---|---|---|---|
B2B Software Technologies Ltd (India) | Listed parent | Dynamics implementation, add-on IP, offshore delivery, Emerging Technologies division | Active |
B2B Softech Inc. (USA) | 100% | US sales and delivery; healthcare IT (GeniusDoc) | Active; sole subsidiary at 31 March 2025 |
B2B ESOP Trust | Controlled trust | Holds 600,000 shares for ESOP/RSU | Active |
Emerging Technologies Division | Internal division | AI, ML, LLMs, agentic chatbots, RPA, blockchain, low-code, cloud migration, cybersecurity | Operations from September 2025 |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Consolidated revenue (INR Cr) | 19.91 | 19.77 | 20.32 | 24.14 | 30.46 |
Standalone parent revenue (INR Cr) | 14.55 | 13.40 | 13.92 | 15.14 | 16.07 |
Derived subsidiary revenue (INR Cr) | 5.36 | 6.37 | 6.40 | 9.00 | 14.39 |
Standalone share of consolidated (%) | 73.1 | 67.8 | 68.5 | 62.7 | 52.8 |
Derived subsidiary share of consolidated (%) | 26.9 | 32.2 | 31.5 | 37.3 | 47.2 |
Standalone revenue growth YoY (%) | 0 | -7.9 | 3.9 | 8.8 | 6.1 |
Derived subsidiary revenue growth YoY (%) | 0 | 18.8 | 0.5 | 40.6 | 59.9 |
Consolidated net profit (INR Cr) | 2.67 | 2.38 | 1.85 | 2.63 | 2.84 |
Standalone net profit (INR Cr) | 2.50 | 2.27 | 1.72 | 2.40 | 2.30 |
Derived subsidiary net profit (INR Cr) | 0.17 | 0.11 | 0.13 | 0.23 | 0.54 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 19.91 | 19.77 | 20.32 | 24.14 | 30.46 |
Revenue growth YoY (%) | 33.6 | -0.7 | 2.8 | 18.8 | 26.2 |
Employee cost (INR Cr) | 10.82 | 11.36 | 12.35 | 15.62 | 19.12 |
Total operating expenses (INR Cr) | 16.83 | 17.72 | 19.10 | 22.21 | 27.93 |
EBITDA excl. other income (INR Cr) | 3.08 | 2.05 | 1.22 | 1.93 | 2.53 |
Other income (INR Cr) | 0.57 | 0.75 | 1.34 | 1.46 | 1.44 |
PBDT, i.e. EBITDA incl. other income (INR Cr) | 3.65 | 2.80 | 2.56 | 3.39 | 3.97 |
Depreciation (INR Cr) | 0.07 | 0.11 | 0.17 | 0.13 | 0.13 |
Operating income, EBIT excl. other income (INR Cr) | 3.01 | 1.94 | 1.05 | 1.80 | 2.40 |
Finance cost (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Pre-tax income (INR Cr) | 3.58 | 2.69 | 2.39 | 3.26 | 3.84 |
Effective tax rate (%) | 25.14 | 11.15 | 23.01 | 19.33 | 25.78 |
Net income (INR Cr) | 2.67 | 2.38 | 1.85 | 2.63 | 2.84 |
EPS basic, bonus-adjusted (INR) | 1.53 | 1.37 | 1.06 | 1.51 | 1.63 |
EPS on pre-bonus share base, derived (INR) | 2.30 | 2.05 | 1.60 | 2.27 | 2.45 |
Dividend per share, pre-bonus base (INR) | 0 | 0 | 0 | 0 | 1 |
Dividend payout (%) | 0 | 0 | 0 | 0 | 40.81 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin excl. other income (%) | 15.47 | 10.37 | 6.00 | 8.00 | 8.31 |
EBITDA margin incl. other income (%) | 18.3 | 14.2 | 12.6 | 14.0 | 13.0 |
Operating (EBIT) margin (%) | 15.1 | 9.8 | 5.2 | 7.5 | 7.9 |
Net margin (%) | 13.4 | 12.0 | 9.1 | 10.9 | 9.3 |
Employee cost as % of revenue (%) | 54.3 | 57.5 | 60.8 | 64.7 | 62.8 |
Other income as % of pre-tax income (%) | 15.9 | 27.9 | 56.1 | 44.8 | 37.5 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 5.03 | 6.22 | 5.40 | 7.48 | 6.47 | 7.66 | 8.28 | 8.04 | 7.39 |
Operating profit (INR Cr) | 0.83 | 0.31 | 0.37 | 0.40 | 0.28 | 0.70 | 1.24 | 0.28 | 0.52 |
Operating margin (%) | 16.50 | 4.98 | 6.85 | 5.35 | 4.33 | 9.14 | 14.98 | 3.48 | 7.04 |
Other income (INR Cr) | 0.37 | 0.41 | 0.36 | 0.35 | 0.60 | 0.25 | 0.46 | 0.16 | 0.73 |
Pre-tax income (INR Cr) | 1.17 | 0.69 | 0.70 | 0.72 | 0.85 | 0.92 | 1.67 | 0.40 | 1.21 |
Net income (INR Cr) | 1.12 | 0.31 | 0.65 | 0.56 | 0.65 | 0.63 | 1.24 | 0.32 | 0.92 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Equity share capital (INR Cr) | 11.59 | 11.59 | 11.59 | 11.59 | 11.59 |
Reserves (INR Cr) | 4.23 | 6.57 | 8.43 | 10.88 | 13.54 |
Total equity (INR Cr) | 15.82 | 18.16 | 20.02 | 22.47 | 25.13 |
Gross borrowings (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Other liabilities (INR Cr) | 1.96 | 1.88 | 2.80 | 2.92 | 3.10 |
Total assets (INR Cr) | 17.78 | 20.04 | 22.82 | 25.39 | 28.23 |
Net fixed assets (INR Cr) | 0.12 | 0.37 | 0.31 | 0.23 | 0.28 |
Investments (INR Cr) | 11.19 | 13.10 | 13.88 | 16.49 | 18.01 |
Other assets incl. receivables and cash (INR Cr) | 6.47 | 6.57 | 8.63 | 8.67 | 9.94 |
Book value per share, bonus-adjusted (INR) | 9.10 | 10.45 | 11.52 | 12.93 | 14.46 |
Investments as % of total assets (%) | 62.9 | 65.4 | 60.8 | 64.9 | 63.8 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 2.04 | 1.84 | 1.49 | 1.57 | 3.31 |
Capex, derived (INR Cr) | 0.05 | 0.33 | 0.10 | 0.06 | 0.18 |
Free cash flow (INR Cr) | 1.99 | 1.51 | 1.39 | 1.51 | 3.13 |
Investing cash flow (INR Cr) | -0.95 | -1.54 | 0.10 | -1.68 | 0.35 |
Financing cash flow (INR Cr) | 0 | 0 | 0 | 0 | -1.16 |
Dividends paid, inferred (INR Cr) | 0 | 0 | 0 | 0 | 1.16 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (INR Cr) | 1.09 | 0.30 | 1.59 | -0.11 | 2.51 |
FCF as % of net income (%) | 74.5 | 63.4 | 75.1 | 57.4 | 110.2 |
Operating cash flow before tax / EBITDA, per Screener (%) | 66 | 90 | 122 | 81 | 131 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | 18.7 | 14.0 | 9.7 | 12.4 | 11.9 |
ROA on average assets (%) | 16.3 | 12.6 | 8.6 | 10.9 | 10.6 |
ROCE, per Screener (%) | 25.06 | 15.60 | 11.31 | 15.20 | 15.84 |
Operating ROIC excl. treasury investments, derived (%) | 48.6 | 34.1 | 13.2 | 24.3 | 25.0 |
Debt to equity (x) | 0 | 0 | 0 | 0 | 0 |
Liquidity proxy: (investments + other assets) / other liabilities (x) | 9.0 | 10.5 | 8.0 | 8.6 | 9.0 |
Asset turnover (x) | 1.22 | 1.05 | 0.95 | 1.00 | 1.14 |
Debtor days | 29.33 | 22.15 | 33.41 | 23.13 | 13.06 |
Inventory days | 8.88 | 12.39 | 17.06 | 23.63 | 32.59 |
Days payable | 25.52 | 6.76 | 29.56 | 1.31 | 3.26 |
Cash conversion cycle (days) | 12.69 | 27.79 | 20.90 | 45.45 | 42.39 |
Revenue by Region and Region Margins & Growth (%)
| Region (proxy) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India-entity revenue, standalone (INR Cr) | 13.92 | 15.14 | 16.07 |
USA-subsidiary revenue, derived (INR Cr) | 6.40 | 9.00 | 14.39 |
India-entity growth YoY (%) | 3.9 | 8.8 | 6.1 |
USA-subsidiary growth YoY (%) | 0.5 | 40.6 | 59.9 |
USA-subsidiary share of total (%) | 31.5 | 37.3 | 47.2 |
Valuation Snapshot
| Metric | Value | Date / source |
|---|---|---|
Last close | INR 21.40 | 19 October 2026 (Screener) |
Market capitalisation | INR 37.2 Cr | 19 October 2026 (Screener) |
52-week high / low | INR 38.00 / INR 15.81. The high was recorded 9 February 2026 and the low 14 January 2026; the mix of bonus-adjusted and unadjusted prices across sources is unclear | Accord Fintech; Screener |
1-year return | –1% (Screener CAGR) / +3.62% (ScanX); timing differences | October 2026 |
3-year price CAGR | 3% | Screener |
5-year price CAGR | 1% | Screener |
10-year price CAGR | 11% | Screener |
6-month return | –30.58% | ScanX, October 2026 |
Shareholders | 9,017 | September 2026 |
Share Price & Returns
| Date | Close (INR) | Basis |
|---|---|---|
21 Nov 2024 | 37.14 | Pre-bonus |
13 Aug 2025 | 32.68 (intraday) | Pre-bonus |
21 Dec 2025 | 29.40 | Pre-bonus |
16 Jan 2026 | 24.85 | Pre-bonus |
3 Jun 2026 | 24.44 | Post-bonus |
22 Jul 2026 | 27.70 | Post-bonus |
9 Oct 2026 | 21.61 | Post-bonus |
19 Oct 2026 | 21.40 | Post-bonus |
Valuation Multiples
| Multiple | B2B Software | Basis |
|---|---|---|
P/E (trailing twelve months) | 12.0x | Screener; TTM net income INR 3.11 Cr |
P/B | 1.48x | Price INR 21.4 / book value INR 14.4 |
EV/Sales (TTM) | 0.61x | EV of about INR 19.2 Cr (market cap 37.2 less investments 18.01) / TTM revenue INR 31.37 Cr |
EV/EBITDA excl. other income (TTM) | 7.0x | EV of about INR 19.2 Cr / TTM operating profit INR 2.74 Cr |
Dividend yield | 3.11% | Screener (INR 1 pre-bonus, about INR 0.67 post-bonus equivalent) |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share, pre-bonus base (INR) | 0 | 0 | 0 | 0 | 1 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 1.16 |
Payout ratio (%) | 0 | 0 | 0 | 0 | 40.81 |
Capital Markets
| Item | Status |
|---|---|
Credit ratings (Moody's, S&P, Fitch, CRISIL, ICRA, CARE, India Ratings) | None. The company is unrated and has no rated debt |
Debt maturity profile | Not applicable: zero borrowings |
Analyst Conclusions
Management guidance: none issued. Consensus expectations: none (no coverage).
Run-rate indicators. Q1 FY27 revenue of INR 7.39 Cr annualises to about INR 29.6 Cr, roughly flat against FY2026's INR 30.46 Cr. Adding the Learnovate order (about INR 1.4 Cr over 6–8 months) and continued Antelope Valley billing (about INR 1.7 Cr a year) points to FY2027 revenue in the INR 30–34 Cr range absent new wins. This is an analyst scenario, not guidance.
Bull case:
-
Hidden operating value. At an EV of about INR 19 Cr and EV/EBITDA of 7x on a business with operating ROIC of about 25% that is growing revenue in double digits (FY2025 +18.8%, FY2026 +26.2%, Q1 FY27 +14.2%), the core is cheap if growth persists.
-
Capital-allocation inflection. The first dividend (40.8% payout), the bonus, a pending split and an INR 18 Cr investment book give room for higher payouts or a buyback that would re-rate the stock.
-
AI and healthcare optionality. If the oncology AI program can be replicated with non-related US practices, the US subsidiary already at about 47% of revenue could keep compounding at 40–60%.
Bear case:
-
Growth quality. About 88% of FY2026 incremental revenue came through the US subsidiary at an implied net margin of about 3.8%. Consolidated net income rose only 8% on 26% revenue growth.
-
Governance overhang. The anchor AI contract is a related-party transaction. The promoter stake has fallen 12.8 points since December 2023. The company has had an auditor change, a director resignation and two CS changes in about 12 months.
-
Earnings dependence on treasury income. Other income was 37.5% of FY2026 pre-tax income and 60% of Q1 FY27 pre-tax income. Operating margin swings from 3.5% to 15.0% quarter to quarter, which makes earnings unreliable.
Concluding analyst verdict.
B2B Software Technologies is a debt-free micro-cap Microsoft Dynamics specialist with a small but real proprietary IP layer. Its financial profile is conservative and its capital efficiency is poor. Over FY2021–FY2026 it compounded revenue at about 15% a year to INR 30.46 Cr, grew net income at about 9% a year to INR 2.84 Cr, and accumulated an INR 18 Cr investment book. That book now underwrites about half its market value. Stripped of treasury assets, the operating business trades at roughly 7x EBITDA while earning about 25% on operating capital. On paper that is undemanding.
The dossier, however, surfaces three issues that keep the discount rational rather than anomalous. First, recent growth is concentrated in a low-margin US subsidiary. The flagship AI contract that underpins the "Emerging Technologies" narrative is a shareholder-approved related-party transaction, not an arm's-length market validation. Second, profitability has not scaled. Operating margins in FY2026 (8.3%) remain about half the FY2022 peak, and other income still props up a third or more of pre-tax profit. Third, governance signals are mixed. Steady promoter selling, an auditor change, a director exit and rapid Company Secretary turnover have occurred alongside shareholder-friendly corporate actions (bonus, first dividend) whose market impact has already faded: the stock is down about 31% over six months.
The investment case therefore hinges less on the AI pivot than on two verifiable developments. The first is whether the company can win non-related Emerging Technologies or Business Central mandates, as the June 2026 East Africa order hints, at margins above 10%. The second is whether the board deploys or distributes its surplus capital. Absent both, the stock is likely to remain a low-liquidity value trap. With both, the re-rating potential is meaningful.
Q2 FY27 margin quality and related-party revenue mix are the next decisive data points.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / appointment | Background | Age | Source |
|---|---|---|---|---|---|
Dr. Ramachandra Rao Nemani | Chief Executive Officer (KMP) | Since 23 August 2014 per MarketScreener; co-built the business from 2000 | Medical doctor (MD); director of B2B Softech Inc., Exotic Granite & Marble Inc. and former Singapore, Malaysia and German group entities | — | Yahoo Finance; MarketScreener; MarketsMojo |
Mr. Bala Subramanyam Vanapalli | Whole-time / Executive Director | Director since 1 October 2014; re-appointed at the 32nd AGM (28 August 2026) | Signs Regulation 30 disclosures; holds ESOP grants | Born 1970 (about 56) | Zauba; Yahoo; ScanX |
Mr. Sunil Nemani | Chief Financial Officer (KMP) | — | — | — | Yahoo Finance |
Dr. Avinash Yaramati (DIN 09804102) | Non-Executive, Non-Independent Director | Additional Director 12 July 2025; regularised 29 September 2025; re-appointed (retire-by-rotation) 28 August 2026 | MS (General Surgery), Mamata Medical College; MBBS, Mahatma Gandhi Medical College & Research Institute; Registrar in Surgical Gastroenterology at Star Hospitals, Hyderabad; academic roles at NIMS and other medical colleges | — | FY2025 Directors' Report; ScanX |
Mr. Suresh Chode (DIN 03473921) | — | Since 30 September 2019 | — | — | Zauba |
Ms. Rajeswari Immani (DIN 07127791) | Director | Since 30 September 2015 | — | — | Zauba |
Mr. Yarava Hari Prasad | Manager, Finance & Accounts | — | — | — | Yahoo |
Mr. Kolli Satish | Technical Head | — | — | — | Yahoo |
Company Secretary | Vacant or unconfirmed. Ms. Yamini Saini was appointed 22 April 2026; a CS resignation took effect 17 July 2026 | — | Ms. Saini: qualified CS with more than 7 years' experience | — | ScanX |
“—” = not publicly disclosed.
Directors' Remuneration
| Executive | Salary | Bonus | Stock (ESOP) | Total | Year / source |
|---|---|---|---|---|---|
Bala Subramanyam Vanapalli | — | Performance bonus approved at the AGMs of September 2025 and August 2026 (amounts not disclosed) | 24,811 options granted November 2025 | INR 5.77 million (reported "pay") | Yahoo Finance (fiscal year not specified, likely FY2025) |
Non-executive directors | Sitting fees (amounts not disclosed) | — | — | — | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
12 Jul 2025 | Yaramati Satyanarayana ceased as Chairman and Non-Executive Director; Dr. Avinash Yaramati appointed Additional Director | Promoter-family succession is likely given the shared surname, but the relationship is not disclosed |
26 Aug 2025 | Woman director's resignation effective | Board approved 12 August 2025 |
29 Sep 2025 | Statutory auditor changed to M. V. Vijaya Kumar & Co. | Also appointed DSMR & Associates as secretarial auditor |
22 Apr 2026 | Yamini Saini appointed CS and Compliance Officer | — |
17 Jul 2026 | CS resignation effective | Second Company Secretary transition within about three months |
28 Aug 2026 | Dr. Yaramati Avinash and Mr. Vanapalli re-appointed | All AGM resolutions passed with more than 99.7% public non-institutional approval |
Shareholding Trend
| Holder category | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|
Promoter & promoter group (%) | 60.05 | 59.83 | 59.83 | 62.66 | 62.46 | 59.63 | 59.59 | 56.53 | 56.53 |
Public (%) | 34.76 | 34.98 | 34.99 | 36.63 | 36.84 | 35.18 | 37.47 | 40.52 | 42.46 |
Others, incl. ESOP trust (%) | 5.18 | 5.18 | 5.18 | 0.70 | 0.70 | 5.18 | 2.93 | 2.93 | 1.00 |
Foreign institutional investors (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Domestic institutional investors (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of shareholders | 8,350 | 8,165 | 8,137 | 8,011 | 8,031 | 7,860 | 8,504 | 9,033 | 9,017 |
Major Shareholders
| Holder | Stake (%) | Shares | Note |
|---|---|---|---|
Ravileela Granites Limited | 13.04 | 1,511,000 | Corporate holder (promoter-group affiliation likely; Dr. Nemani is a director of Exotic Granite & Marble Inc.) |
Srinivas Reddy Parvatha Reddy | 1.83 | 212,410 | Individual |
J. Vasantha Reddy | 0.60 | 69,954 | Individual |
Harshini | 0.16 | 18,000 | Individual |
Samantha Reddy | 0.14 | 15,900 | Co-founder |
Neelam Jayanth Reddy | 0.07 | 7,900 | Individual |
Competitive Landscape
Competitors by Segment
| Segment | Named competitors | Positioning vs. B2B Software |
|---|---|---|
Microsoft Dynamics implementation (India and global) | Sonata Software (Microsoft partner of more than 30 years; member of the Microsoft Inner Circle); Kellton Tech Solutions (Hyderabad; ERP and digital transformation); Hitachi Solutions; Cognizant, Infosys and TCS Dynamics practices; numerous private Indian Dynamics partners | B2B is a niche, sub-scale player without any Inner Circle status of the kind Sonata cites |
ERP products (India-origin) | Ramco Systems (own ERP, payroll and aviation suites) | Ramco is a full-stack ERP vendor; B2B sells add-ons on Microsoft's platform |
Hyderabad small-cap IT services | Tera Software; Kellton Tech; TechNVision Ventures; Blue Cloud Softech Solutions | Comparable listing tier; most are larger and faster-growing |
ERP alternatives (platform competitors) | Oracle (NetSuite), SAP Business One, Fujitsu (PitchBook lists Fujitsu, Biprogy, Fujitsu Frontech North America and Oracle as competitors) | Platform-level competition affecting Dynamics share |
US physician practice management / EMR | Large US EHR and practice-management vendors (Epic, Oracle Health, athenahealth, eClinicalWorks are the industry's major names; no head-to-head data available) | GeniusDoc is a niche product with minimal disclosed scale |
AI / emerging technologies services | Every Indian IT services firm, from Tier-1 to micro-cap (e.g. Sonata, Saksoft, Happiest Minds) | B2B is a new entrant with one anchor (related-party) client |
Peer Comparison FY2026
| Metric | B2B Software | Sonata Software | Kellton Tech | Ramco Systems | Tera Software |
|---|---|---|---|---|---|
Revenue (INR Cr) | 30.46 | 10,701.2 | 1,216.94 | 700.95 | 238.05 |
Revenue growth YoY (%) | 26.2 | 5.4 | 10.9 | 18.5 | 121.9 |
Operating / EBITDA margin (%) | 8.3 | 6.9 | 11.8 | 22.6 | 15.4 |
Net income (INR Cr) | 2.84 | 464.4 | 91.67 | 41.84 | 24.80 |
Net margin (%) | 9.3 | 4.3 | 7.5 | 6.0 | 10.4 |



